European expansion Shockwave Medical has demonstrated a history of international market entry, including the European launch of its IVL system for peripheral arterial disease in 2017 after CE marking in 2015. This suggests readiness to scale into new regional markets and potential for channel partners or distributors to accelerate Europe-wide sales and adoption.

Javelin roll-out Recent launches of the Javelin peripheral IVL catheter in the US and Europe, described as path-clearing lithotripsy devices, indicate a growing product family and expanded indications. This presents cross-selling opportunities to existing cardiovascular accounts and hospitals, as well as partnerships with interventional centers seeking advanced plaque modification tools.

PAD focus Clinical attention on peripheral arterial disease with IVL technology signals a complementary market to coronary calcified lesions. Targeting PAD programs, endovascular labs, and vascular surgery groups can broaden contract opportunities for both devices and associated training, services, and digital support platforms.

manufacturing modernization A $40M investment in a digitalized catheter manufacturing facility suggests scalable production capacity and potential for faster lead times, larger order volumes, and improved global supply reliability. This supports sales forecasts for large health systems and multi-site deployments.

financial momentum With annual revenue in the mid hundreds of millions and a growing product suite, Shockwave Medical is positioned to pursue strategic partnerships, co-development deals, and contract wins with large hospital networks, while presenting a compelling value proposition for distributors and value-based purchasing arrangements.